Xavier Leleu

Q: What Schools Are Affiliated With Xavier Leleu

Xavier Leleu is affiliated with the following schools: University of Poitiers, University of Salamanca, Harvard University

Xavier Leleu's AcademicInfluence.com Rankings

Xavier Leleu

Philosophy

#9319

World Rank

#12858

Historical Rank

Logic

#6302

World Rank

#7810

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Xavier Leleu Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Xavier Leleu's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) (2949)
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. (2012) (1017)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. (2011) (877)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma (2017) (776)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (2019) (555)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (2019) (520)
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. (2007) (453)
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. (2015) (436)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (2012) (423)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. (2009) (419)
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). (2010) (413)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (2012) (409)
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. (2006) (355)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma (2018) (327)
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. (2009) (320)
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. (2001) (319)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (2019) (316)
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. (2002) (314)
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. (2013) (309)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. (2016) (297)
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (2013) (289)
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. (2012) (285)
Bone Marrow Microenvironment in Multiple Myeloma Progression (2012) (270)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. (2018) (254)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. (2007) (253)
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. (2007) (245)
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. (2014) (241)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study (2016) (235)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (2017) (222)
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop (2013) (216)
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. (2013) (216)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study (2020) (212)
MYD88 L265P mutation in Waldenstrom macroglobulinemia. (2012) (209)
Prognostic role of circulating exosomal miRNAs in multiple myeloma. (2017) (202)
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. (2018) (195)
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group (2016) (189)
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248 (2007) (178)
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). (2013) (172)
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors (2010) (157)
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel (2018) (152)
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. (2009) (149)
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. (2014) (144)
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. (2007) (144)
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. (2003) (142)
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. (2009) (141)
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma (2012) (128)
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21) (2005) (125)
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. (2009) (125)
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. (2008) (120)
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial (2020) (117)
Gemcitabine as a single agent in the treatment of relapsed or refractory low‐grade non‐Hodgkin's lymphoma (2001) (112)
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma (2014) (112)
Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia (2010) (110)
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. (2014) (110)
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. (2009) (109)
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma (2008) (108)
Targeting NF-kappaB in Waldenstrom macroglobulinemia. (2008) (101)
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. (2015) (100)
Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. (2016) (99)
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) (2016) (98)
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. (2007) (96)
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? (2015) (94)
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial (2019) (92)
Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma (2006) (91)
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial (2021) (89)
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) (2020) (89)
Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia (2014) (87)
Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. (2006) (86)
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. (2015) (85)
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. (2016) (83)
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients (2014) (81)
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor (2004) (80)
Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice (2016) (79)
Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma (2007) (78)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. (2019) (78)
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. (2008) (77)
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. (2020) (73)
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials (2013) (73)
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. (2008) (72)
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. (2016) (71)
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. (2007) (71)
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network (2020) (70)
Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma (2012) (70)
MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome (2014) (69)
Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia (2008) (68)
Upregulation of miR-135b Is Involved in the Impaired Osteogenic Differentiation of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients (2013) (68)
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. (2021) (67)
The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma (2016) (67)
Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia (2011) (65)
A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis (2014) (64)
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. (2018) (63)
Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial (2015) (63)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT (2018) (63)
Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging. (2010) (62)
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma (2020) (61)
Efficacy of lenalidomide in POEMS syndrome: A retrospective study of 20 patients (2013) (61)
Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (2005) (61)
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis (2018) (59)
Proteomic analysis of waldenstrom macroglobulinemia. (2007) (58)
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. (2017) (57)
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study (2017) (57)
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network (2017) (57)
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. (2016) (57)
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma (2013) (56)
Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment (2008) (56)
Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma (2014) (55)
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo (2013) (55)
MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs (2013) (54)
HLA-G and lymphoproliferative disorders. (2003) (54)
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma (2011) (52)
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia (2016) (52)
Epigenetic Silencing of the Tetraspanin CD9 during Disease Progression in Multiple Myeloma Cells and Correlation with Survival (2008) (50)
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia (2017) (49)
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial (2020) (49)
Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway (2012) (48)
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes (1999) (48)
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. (2015) (48)
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. (2018) (48)
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688) (2019) (47)
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia (2008) (46)
Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial (2011) (46)
The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia (2010) (46)
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. (2006) (44)
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma (2017) (43)
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience (2012) (43)
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia (2013) (42)
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial (2020) (41)
Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant (2008) (41)
Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Kr (2016) (41)
Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia (2007) (40)
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations (2021) (39)
Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study (2019) (39)
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients (2018) (39)
Bendamustine is effective in T‐Cell prolymphocytic leukaemia (2015) (38)
Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients (2007) (38)
The role of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia (2011) (38)
High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. (2009) (38)
Bortezomib (VELCADE®) Plus Dexamethasone as Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Preliminary Results of an IFM Phase II Study. (2004) (37)
Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma (2014) (37)
Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. (2009) (37)
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab (2021) (36)
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis (2020) (35)
IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma (2014) (35)
Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma (2018) (35)
Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients with AL (Primary) Amyloidosis: Results of the French Multicentric Randomized Trial (MAG and IFM Intergroup). (2005) (34)
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. (2021) (34)
Characterization of familial Waldenstrom's macroglobulinemia. (2004) (34)
Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study (2019) (33)
Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells (2015) (33)
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (2021) (32)
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. (2016) (32)
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma (2014) (32)
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial (2015) (32)
Efficacy of a low dose of thalidomide in advanced multiple myeloma. (2002) (32)
Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy (2007) (31)
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study (2015) (31)
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients (2014) (31)
Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM (2014) (31)
Risk factors for severe infection in patients with hairy cell leukemia: a long‐term study of 73 patients (2009) (30)
A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients. (2010) (30)
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. (2016) (29)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. (2021) (29)
Novel M-component based biomarkers in Waldenström's macroglobulinemia. (2011) (29)
Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study (2010) (28)
Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients. (2020) (28)
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients (2016) (28)
Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia. (2012) (28)
Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01–01 trial (2007) (28)
Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model (2013) (28)
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. (2018) (27)
Plasma cell growth fraction using Ki‐67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I (2007) (27)
Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation (1999) (27)
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma (2019) (26)
Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition (2017) (26)
High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02 (2011) (26)
Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study. (2020) (25)
Efficacy and safety profile of long‐term exposure to lenalidomide in patients with recurrent multiple myeloma (2013) (25)
Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies (2014) (25)
Sustained treatment‐free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T‐cells (2019) (24)
A GEIL flow cytometry consensus proposal for quantification of plasma cells: Application to differential diagnosis between MGUS and myeloma (2011) (24)
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (24)
Understanding the multiple biological aspects leading to myeloma (2014) (24)
Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program (2011) (24)
Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02) (2017) (23)
Lenalidomide is safe and active in Waldenström macroglobulinemia (2015) (23)
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. (2019) (23)
Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14) (2013) (23)
IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom’s Macroglobulinemia (WM). (2006) (22)
Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma (2017) (22)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. (2022) (21)
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. (2022) (21)
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. (2006) (21)
Prognostic value of PINI index in patients with multiple myeloma (2012) (21)
Pomalidomide for multiple myeloma (2014) (20)
Alcohol use disorders in French hospital patients. (1997) (20)
Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02 (2010) (20)
Targeting NF-B in Waldenstrom macroglobulinemia (2008) (20)
High-throughput genomic analysis in Waldenström's macroglobulinemia. (2011) (20)
Update on therapeutic options in Waldenström macroglobulinemia (2009) (20)
The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia (2008) (20)
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma (2016) (20)
Novel agents in the treatment of Waldenström's macroglobulinemia. (2007) (20)
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia (2008) (19)
Memory loss during lenalidomide treatment: a report on two cases (2013) (19)
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond (2021) (19)
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. (2018) (19)
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia (2009) (19)
Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia (2009) (19)
Low‐dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment‐free remission in chronic myeloid leukemia patients: Results of a retrospective study (2020) (18)
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. (2019) (18)
Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma. (2012) (18)
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020 (2020) (18)
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study (2018) (18)
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? (2017) (18)
Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results. (2009) (18)
Response to pneumococcal vaccination in multiple myeloma (2019) (17)
Myélome multiple : diagnostic clinique et perspective de traitement. Recommandations de l’International Myeloma Working Group (IMWG) (2011) (17)
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. (2007) (17)
Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study (2010) (17)
Novel therapeutic avenues in myeloma: changing the treatment paradigm. (2007) (17)
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). (2019) (17)
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. (2021) (17)
Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM) (2016) (17)
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) (2015) (16)
Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. (2012) (16)
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis (2020) (16)
SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia. (2009) (16)
The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma (2013) (16)
Observational study of vaccination in cancer patients: How can vaccine coverage be improved? (2019) (16)
Proteomics analysis in post‐transplant lymphoproliferative disorders (2008) (16)
Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM) (2008) (15)
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US (2021) (15)
Melflufen for relapsed and refractory multiple myeloma (2020) (15)
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial (2019) (15)
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma (2019) (15)
Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders. (2019) (15)
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis (2012) (15)
Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue: A Clinicopathologic Study of 92 Patients With Amyloid-containing Minor Salivary Gland Biopsies (2015) (14)
A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma (2010) (14)
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma (2020) (14)
Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens (2006) (14)
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study (2020) (13)
Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. (2007) (13)
Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma (2017) (13)
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study. (2010) (13)
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial (2019) (12)
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma (2021) (12)
First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma (2020) (12)
Initial treatment of transplant-ineligible patients in multiple myeloma (2014) (12)
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. (2016) (12)
Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial. (2013) (11)
Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome ( (2017) (11)
1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients (2012) (11)
The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and monoclonal gammopathy of renal significance. (2018) (11)
Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia (2015) (11)
Mise au point sur le traitement du myélome multiple (2006) (11)
Emerging drugs in multiple myeloma (2007) (11)
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies (2020) (11)
Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenström's macroglobulinemia: association with FcγRIIa polymorphism (2006) (11)
Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple Myeloma (2004) (11)
Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival. (2005) (11)
[Waldenström's macroglobulinemia]. (2010) (11)
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment (2017) (10)
Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia (WM) patients treated with nucleoside analogues (2007) (10)
S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (2019) (10)
Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES (2013) (10)
Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab (2019) (10)
Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom’s Macroglobulinemia by Gene Expression Profiling. (2007) (10)
PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG ) (2014) (10)
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma (2019) (10)
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation (2014) (10)
PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY (2019) (9)
Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results. (2021) (9)
Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs (2009) (9)
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR‐MM) (2016) (9)
Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia. (2013) (9)
Establishment of a Waldenstrom’s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice. (2005) (9)
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials (2018) (9)
Front line treatment of elderly multiple myeloma in the era of novel agents (2008) (9)
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk (2021) (9)
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. (2017) (9)
IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia (2016) (9)
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma (2018) (9)
Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature. (2022) (8)
Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). (2021) (8)
Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial (2012) (8)
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients (2014) (8)
Treatment of Newly Diagnosed Elderly Multiple Myeloma. (2016) (8)
Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. (2019) (8)
Faculty Opinions recommendation of Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. (2008) (8)
Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score (2020) (8)
Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial (2016) (8)
Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. (2006) (8)
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone (2017) (8)
Individuals Expressing FcγRIIIA-158 V/V and V/F Show Increased NK Cell Surface Expression of FcgRIIIA (CD16), Rituximab Binding, and Demonstrate Higher Levels of ADCC Activity in Response to Rituximab. (2005) (8)
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial (2022) (8)
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma (2021) (7)
Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. (2011) (7)
New hope for relapsed and refractory multiple myeloma. (2013) (7)
Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy (2018) (7)
Thrombosis in myeloma treated with IMiDs. (2012) (7)
Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization (2015) (7)
Carfilzomib weekly 20/56 mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma (2018) (7)
Targeted therapies in Waldenström macroglobulinemia. (2008) (7)
Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myélome (IFM) 2009-01 protocol. (2012) (7)
Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (2011) (7)
Role of proteasome inhibition in Waldenström's macroglobulinemia. (2009) (7)
Targeting the bone marrow in Waldenstrom macroglobulinemia. (2011) (7)
Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial (2010) (7)
Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study (2019) (7)
Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network (2009) (7)
Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study (2015) (7)
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) (2014) (6)
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice? (2016) (6)
Low-dose biplanar skeletal survey versus digital skeletal survey in multiple myeloma (2013) (6)
Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom’s Macroglobulinemia. (2006) (6)
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial (2022) (6)
Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma (2004) (6)
Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT). (2017) (6)
Age‐related health care disparities in multiple myeloma (2018) (6)
Isolated neurological relapse following stem cell transplantation in plasma cell leukemia: a report of two cases (1999) (6)
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma (2014) (6)
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk (2020) (6)
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA‐MM subgroup analysis (2021) (6)
The Value Of Serum Free Light Chain Monitoring Compared To Urinary Bence-Jones Measurement In Light Chain Only Myeloma (2013) (6)
[Thalidomide: mechanisms of action and new insights in hematology]. (2005) (6)
Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria (2018) (6)
Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study. (2009) (6)
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT (2020) (6)
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics (2011) (6)
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. (2021) (5)
KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation (2022) (5)
The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma. (2006) (5)
Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study (2017) (5)
Psychometric Performance Of The EORTC Quality-Of-Life Core Questionnaire (QLQ-C30) and QLQ-Multiple Myeloma (QLQ-MY20) In Relapsed/Refractory Multiple Myeloma (RRMM) (2013) (5)
The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial (2018) (5)
S1605 HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM) (2019) (5)
Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia (2017) (5)
Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. (2007) (5)
Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM). (2022) (5)
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond. (2018) (5)
Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors (2018) (5)
Bortezomib and Waldenstrom's macroglobulinemia. (2009) (5)
Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial. (2020) (5)
Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. (2019) (5)
Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma (2005) (5)
Novel therapeutic agents in Waldenström's macroglobulinemia. (2009) (5)
HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex). (2020) (5)
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT (2020) (5)
Bortezomib in Waldenstrom’s Macroglobulinemia (2011) (5)
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods (2021) (5)
[Orbital granulocytic sarcoma revealing acute myeloblastic syndrome: a case study]. (2004) (5)
Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03 (2019) (5)
Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis (2019) (5)
First Large Prospective Study For Patients With Primary Plasma Cell Leukemia: Bortezomib-Doxorubicine-Dexamethasone/Bortezomib-Cyclophosphamide-Dexamethasone Regimens As Induction Before Stem Cell Transplantation Followed By Consolidation With Lenalidomide-Bortezomib-Dex Or Allograft. (a study of th (2013) (4)
Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group (2016) (4)
Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment. (2009) (4)
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma (NHL) with the ACVBP regimen. A GELA (Groupe d'Etude des Lymphomes de l'Adulte) cohort study on 2849 patients. (2001) (4)
Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia (2008) (4)
Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials (2017) (4)
Imatinib Mesylate (Gleevec®) Produces Responses in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia. (2007) (4)
The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenström macroglobulinemia patients aged 65 years or less (2008) (4)
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis (2020) (4)
A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (2019) (4)
Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04. (2022) (4)
Clinical Characteristics, Chromosomal Abnormalities and Outcomes in Very Elderly Patients with Multiple Myeloma: The IFM Experience (2012) (4)
Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom’s Macroglobulinemia. (2007) (4)
A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenstrom’s Macroglobulinemia. (2005) (4)
Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients. (2022) (4)
Waldenstrom macroglobulinemia. (2008) (4)
Circulating exosomal microRNAs are critical prognostic markers independent of cytogenetics and International Staging System in Multiple Myeloma (2015) (4)
TCL1 expression patterns in Waldenström macroglobulinemia (2016) (4)
Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia (2015) (4)
Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis (2013) (4)
Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma (2020) (4)
Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM) (2013) (4)
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (4)
The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia. (2006) (4)
HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents (2020) (4)
Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study (2019) (4)
Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM). (2006) (4)
BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia (2016) (3)
Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom’s Macroglobulinemia (WM). (2006) (3)
Serum Free Light Chain in Waldenstrom Macroglobulinemia. (2006) (3)
Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria? (2015) (3)
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations (2022) (3)
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (2021) (3)
Genome Wide SNP Analysis Reveals Frequent Cryptic Clonal Chromosomal Aberrations Including Uniparental Disomy (UPD) in Waldenstrom's Macroglobulinemia. (2009) (3)
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial (2021) (3)
Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study (2020) (3)
Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA. (2020) (3)
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes (2022) (3)
Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom’s Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response. (2005) (3)
Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort (2022) (3)
Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article (2021) (3)
Founding Precision Therapy in 1q-Amplified Multiple Myeloma (2018) (3)
[Free light chains assay: Indications and methods]. (2019) (3)
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma (2021) (3)
Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma. (2013) (3)
Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients (2020) (3)
A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study: MM‐230 (2018) (3)
Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma (2015) (3)
Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis (2022) (3)
Bortezomib-doxorubicin-cyclophosphamide-dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the IFM (2016) (3)
Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs (2016) (3)
HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety (2019) (3)
Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone (2020) (3)
Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques (2014) (3)
Light Chain Escape in Multiple Myeloma (2018) (3)
An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma (2021) (3)
In Vivo Mobilization of Multiple Myeloma Cells Out of the Bone Marrow Using the CXCR4 Inhibitor AMD3100 and Bortezomib: Implications for Sensitization of Myeloma Cells to Apoptosis. (2007) (3)
The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma (2020) (3)
Novel agents in Waldenstrom Macroglobulinemia. (2010) (3)
Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM) (2021) (3)
Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study (2015) (3)
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study (2021) (3)
Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA (2019) (3)
Prolonged Overall Survival with Pomalidomide and Dexamethasone in Myeloma Characterized with End Stage Disease. (2012) (3)
Bortezomib and Waldenstrom's macroglobulinemia (2009) (3)
Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results. (2007) (3)
EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE. (2021) (3)
The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom’s Macroglobulinemia. (2006) (3)
MELISSE, a Large Multicentric Observational Study to Determine Criteria and Risk Factors of Thromboembolism for Patients with Multiple Myeloma Treated with Immunomodulator Drugs (2010) (2)
The PI3K/Akt Pathway Is an Important Regulator of Homing and Adhesion in Waldenstrom’s Macroglobulinemia. (2006) (2)
Long‐term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98‐LEDGF rearrangement (2019) (2)
[IMiDs in hematology]. (2011) (2)
Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort (2021) (2)
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. (2020) (2)
Rituximab-Cyclophosphamide-Dexamethasone (RCD) Combination In the Management of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukaemia (2010) (2)
The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM). (2007) (2)
PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US (2019) (2)
Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465. (2006) (2)
Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma (2014) (2)
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. (2022) (2)
B525 Regulation of Histone Deacetylase in Waldenström Macroglobulinemia (2009) (2)
Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM) (2012) (2)
Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study (2012) (2)
Lin28B/Let-7 Axis Regulates Multiple Myeloma Proliferation By Enhancing c-Myc and Ras Survival Pathways (2013) (2)
Waldenström's Macroglobulinemia: new therapeutic options (2008) (2)
Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex (2011) (2)
New Therapeutic Approaches for Waldenstrom Macroglobulinemia. (2010) (2)
Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM). (2007) (2)
Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel (2020) (2)
Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma (2016) (2)
Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. (2007) (2)
Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study (2021) (2)
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone (2021) (2)
Evaluation of gemcitabine in relapsed or refractory multiple myeloma. (2004) (2)
The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone (2019) (2)
Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients (2012) (2)
Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study. (2021) (2)
KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation (2022) (2)
Bendamustine, Bortezomib and Dexamethasone (BVD) In Elderly Patients With Multiple Myeloma In First Relapse: Final Analysis Of The Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial (2013) (2)
Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study (2018) (2)
CXCR7 Regulates SDF-1 Induced Adhesion and Homing in Multiple Myeloma. (2008) (2)
Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial. (2021) (2)
Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738) (2013) (2)
Real-world use of carfilzomib among multiple myeloma patients with at least one prior therapy. (2019) (2)
Hevylite® to Monitor Response to Therapy in Multiple Myeloma (2014) (2)
Abnormal Expression of the Plasma Cell Differentiation Factor X-Box Protein 1 (Xbp-1) in Waldenstrom’s Macroglobulinemia. (2005) (2)
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (2019) (2)
Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study (2021) (2)
Polymorphisms in FcγRIIIA Are Genetically Linked to FcγRIIA and May Account for the Primary Predictive Role Ascribed to Polymorphisms in FcγRIIIA-158 in Determining Rituximab Responses. (2005) (2)
Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (2)
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis (2020) (2)
Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study (2020) (2)
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones (2021) (2)
Founding precision therapy for 1q-amplified multiple myeloma (2019) (2)
French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry (2022) (2)
TP53 Mutation in Waldenstrom Macroglobulinemia (2016) (2)
Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 172 Patients (2015) (2)
Hevylite®, a New Marker of Tumor Measurement In Waldenstrom Macroglobulinemia (2010) (2)
Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study (2019) (2)
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis (2020) (1)
Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study (2020) (1)
Multiple myeloma: the puzzle is finally completed. (2014) (1)
Myeloma, IMiDs and thrombosis (2013) (1)
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. (2022) (1)
Risk Stratification of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy (2021) (1)
Waldenström macroglobulinemia and relationship to immune deficiency (2021) (1)
Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03) (2019) (1)
Final Analysis of MELISSE, a Large Multicentric Observational Study to Determine Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Treated with Immunomodulator Drugs (2011) (1)
A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial (2022) (1)
Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population (2019) (1)
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens (2012) (1)
PCN318 CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE (2019) (1)
Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe (2022) (1)
Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd (2013) (1)
A20 Gene Deregulation In Waldenstrom's Macroglobulinemia. (2010) (1)
Faculty Opinions recommendation of A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. (2012) (1)
Long-Term Exposure to Pomalidomide-Dexamethasone in Pts with Refractory Myeloma (2014) (1)
MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis (2021) (1)
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study (2022) (1)
Évolution inhabituelle de manifestations auto-immunes au décours d’une primo-infection à cytomegalovirus révélant tardivement un lymphome de la zone marginale (1998) (1)
Pomalidomide - An appraisal of its clinical development and role in the treatment of relapsed/refractory multiple myeloma (2015) (1)
Regulation of Histone Deacetylase in Waldenström Macroglobulinemia (2008) (1)
Osteolytic Lesion with Thick Sclerotic Walls and Demyelinating Polyneuropathy (2012) (1)
Impaired Osteogenic Differentiation of Mesenchymal Stem Cells Derived From Multiple Myeloma Patients Is Associated with a Failure In the Deactivation of the NOTCH Pathway (2010) (1)
Heterogeneous Bcl-2 Family Expression In Waldenström Macroglobulinemia Determines Response To Inducers Of Intrinsic Apoptosis (2013) (1)
IgA Hevylite® Test As a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA Myeloma (2012) (1)
Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients (2014) (1)
Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years (2016) (1)
Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies (2022) (1)
Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM). (2007) (1)
Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001. (2020) (1)
RD Vs. VRD: What Is the First-Line, Real-Life Management of Multiple Myeloma Patients Ineligible for Stem Cell Auto Transplantation in the Emmy Cohort? (2021) (1)
P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY (2022) (1)
TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia (2008) (1)
Sequence Analysis in the BLYS and APRIL Receptor TACI Reveals Novel Variants with a Potential Pathogenetic Role in Waldenstrom’s Macroglobulinemia (WM). (2005) (1)
macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström (2014) (1)
Increased prevalence of monoclonal gammopathy, abnormal immunoglobulin levels, and recurrent infections in family members of patients with familial Waldenstrom's macroglobulinemia (2008) (1)
[Primary biliary cirrhosis revealed by autoimmune thrombopenic purpura]. (1998) (1)
The EOS ® System for the Detection of Bone Lesions in Patients with Multiple Myeloma, (2011) (1)
Consolidation and maintenance in de novo first-line multiple myeloma with modern agents (2015) (1)
Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study (2020) (1)
Efficacy of Lenalidomide in Patients with Multiple Myeloma Previously Treated by Melphalan-Prednisone and Thalidomide (2012) (1)
Levels of Discordance Between Patients’ and Physicians’ Perceptions of Patients’ Health-Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM) – a Cross-Cultural Perspective (2015) (1)
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma (2022) (1)
Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study (2020) (1)
A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study (2018) (1)
S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS (2022) (1)
Continued Treatment Duration, Drug dosing and Health-Related Quality Of Life (HRQoL) Of Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Receiving 2nd and 3rd Line Treatments: Results From a European Multicentre Study (2013) (1)
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment (2022) (1)
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose (2021) (1)
Novel Options of Therapy in Waldenstro¨m Macroglobulinemia (2007) (1)
Genetic Linkage of FcγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy (2007) (1)
[Prognostic factors and new treatments of multiple myeloma]. (2006) (1)
P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (2022) (1)
IgG and IgA hypogammaglobulinemia is pervasive in Waldenstrom's macroglobulinemia (WM) and persists regardless of response or type of therapeutic intervention (2007) (1)
[Treatment of multiple myeloma]. (2006) (1)
PO-82 Impede VTE vs saved scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose? (2021) (1)
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients (2020) (1)
Targeting the Anaphase Promoting Complex/Cyclosome (APC/C) in Multiple Myeloma (2014) (1)
Faculty Opinions recommendation of Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. (2008) (1)
Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma. (2018) (1)
Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma (2019) (1)
POSC34 Comparative Efficacy and Safety of Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Using a Matching-Adjusted Indirect Comparison (2022) (1)
Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel (2022) (1)
[Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation]. (2015) (1)
A key to the quest? (2014) (1)
Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma (2015) (1)
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study (2022) (1)
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis (2020) (1)
Smoldering multiple myeloma: biology, clinical manifestations and management (2021) (1)
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study (2022) (1)
Carfilzomib weekly-melphalan-prednisone in untreated elderly multiple myeloma: IFM2012-03. (2017) (1)
Real-World Use of Carfilzomib Therapy Among Patients With Existing Cardiovascular Medical History: An Analysis of a Prospective Observational Study (2019) (1)
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit (2022) (1)
Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. (2022) (1)
S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS (2019) (1)
Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study (2022) (1)
Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia. (2006) (1)
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly (2021) (1)
Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study (2022) (1)
Real-World Evidence of the Use of Carfilzomib and Dexamethasone According to Age Subgroup: An Interim Analysis From a Prospective Observational Study (2019) (1)
Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma. (2021) (1)
Impact of Pneumococcal Vaccination on Multiple Myeloma (2017) (1)
[Waldenström macroglobulinaemia]. (2019) (1)
Don't Be So Negative About Negative Results (2013) (0)
Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry (2022) (0)
PF601 EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY (2019) (0)
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma (2015) (0)
Hepatitis C Viral Infection Is Not Associated with Waldenstrom’s Macroglobulinemia. (2005) (0)
antitumor activity in Waldenström macroglobulinemia Protein kinase C inhibitor enzastaurin induces in vitro and in vivo (2008) (0)
Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma (2007) (0)
Phase 1/2 study of car ﬁ lzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma (2015) (0)
A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party (2021) (0)
B556 CXCR7 Regulates SDF-1 Induced, Adhesion, Homing, and Signaling in Multiple Myeloma (2009) (0)
[Smoldering multiple myeloma]. (2014) (0)
MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies (2021) (0)
The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia (2010) (0)
MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies (2020) (0)
IgM k and IgM l Measurements for the Assessment of Patients with Waldenstr € om ' s (2016) (0)
Safety and Utilization of Midline Catheters in the Management of Acute Myeloid Leukemia: A Single Center Experience (2019) (0)
CLINICAL TRIALS OBSERVATIONS BDR in newly diagnosed patients with WM: ﬁ nal analysis of a phase 2 study after a minimum follow-up of 6 years (2017) (0)
Faculty of 1000 evaluation for A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. (2012) (0)
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03 (2022) (0)
Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2017) (0)
Estimating the Price of Progress (2012) (0)
B in Waldenstrom macroglobulinemia κ Targeting NF (2013) (0)
Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 Aspire and Endeavor Trials (2018) (0)
Prevalence of Alcohol Use Disorders in Hospital Patients in One Area of France (1997) (0)
Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (2022) (0)
Risk and Response Adapted Conventionnal Treatment Strategy In AL Amyloidosis: The French Experience Since 2007 (2013) (0)
Faculty Opinions recommendation of Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. (2013) (0)
Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma. (2010) (0)
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma (2023) (0)
Reaching a Consensus on the Definition of Complete Response in Myeloma (2011) (0)
Pomalidomide for multiple (2014) (0)
HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (2020) (0)
Profile of Long-Term Survivors in Multiple Myeloma (2019) (0)
Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma. (2020) (0)
Association of Donor-Recipient HLA Matching with Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation: A Study from the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (0)
Role of proteasome inhibitors as treatment of multiple myeloma (2006) (0)
EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001 (2020) (0)
Faculty Opinions recommendation of Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. (2008) (0)
P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY) (2022) (0)
Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/ Relapsed or Refractory Multiple Myeloma (2019) (0)
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study (2023) (0)
P943: SURVIVAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA IN FRANCE: A COHORT STUDY USING THE FRENCH NATIONAL HEALTHCARE DATABASE (SNDS) (2022) (0)
Plasma cell leukaemia (2005) (0)
PS1412 POMALIDOMIDE 3RD LINE VERSUS 4TH LINE FOR IN EARLY RELAPSED REFRACTORY MULTIPLE MYELOMA (2019) (0)
P-220: Use of Carfilzomib regimens in patients with Multiple Myeloma refractory to CD38 antibodies: a subgroup analysis from a prospective observational study (2021) (0)
Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party (2018) (0)
Regulation of the New CXCR7 Receptor in Plasma Cell Dyscrasias. (2007) (0)
Gene Transcriptional Activity Analysis in the 6q Region in Waldenstrom Macroglobulinemia (WM) Using ChIP-on-Chip Technology (2008) (0)
Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients (2013) (0)
P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER (2022) (0)
macroglobulinemia SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom (2013) (0)
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice (2021) (0)
[Pomalidomide for multiple myeloma]. (2015) (0)
Depth of Response to ≥VGPR at Completion of Induction Influences Outcome Post ASCT, on Behalf of the Tunisian Myeloma Study Group (2016) (0)
Global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients: the Insight-MM Study (2016) (0)
Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA (2021) (0)
B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenström Macroglobulinemia (2012) (0)
Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma (2018) (0)
Biological Sequelae of TRAF2 Downregulation in Waldenstrom Macroglobulinemia Cells. (2007) (0)
Thalidomide in multiple myeloma in the elderly (2009) (0)
Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients (2021) (0)
Trafficking of Multiple Myeloma Cells: What Regulates Homing, Adhesion, and Mobilization of Multiple Myeloma to and from the Bone Marrow Niches (2009) (0)
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma (2021) (0)
P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE (2022) (0)
Diagnostic and prognostic use of FDG-PET scans in Waldenstrom's macroglobulinemia. (2009) (0)
B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci (2014) (0)
PKC412, a Small Molecule Tyrosine Kinase Inhibitor, Regulates Survival and Proliferation Pathways in Waldenström Macroglobulinemia (2008) (0)
Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial (2019) (0)
POSB404 Therapeutic Management of Multiple Myeloma and Healthcare Resource Assessment By Matching the Emmy Cohort to the Data of the National Health Data System (SNDS) in France (2022) (0)
Early PET-CT to Guide Escalated Therapy in Advance Stage Hodgkin Lymphoma (2017) (0)
Immunophenotypic Analysis Using CD80 and CD86 Staining Improves the Diagnosis of Waldenstrom's Macroglobulinemia by Evidencing a CD80+/CD86- Profile. (2009) (0)
P15: EVOLUTION OF MULTIPLE MYELOMA TREATMENT PATTERNS FROM 2015 THROUGH 2019: REAL-WORLD EVIDENCE FROM A EUROPEAN DATABASE STUDY (2022) (0)
P-255: Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) in real-life context: interim analysis of the retrospective IMAGE study (2022) (0)
Prévention des complications liées au traitement des hémopathies Prevention of treatment-related side effects in hematology (2005) (0)
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial (2021) (0)
Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma. (2009) (0)
Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study (2022) (0)
Old, But Not Too Old (2012) (0)
P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 (2022) (0)
R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry study (2020) (0)
A Novel Real-Time In Vivo Homing Model of Multiple Myeloma. (2006) (0)
Skin Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 53 Patients (2015) (0)
MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM) (2021) (0)
Resveratrol Exerts AntiproliferativeActivity and Induces Apoptosis inWaldenstro« m’s Macroglobulinemia (2008) (0)
P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM). (2022) (0)
Treatment of elderly patients with myeloma (2015) (0)
Effectiveness of Second Line Treatment in AL Amyloidosis Patients Refractory to M-Dex. (2009) (0)
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM) (2021) (0)
Morphology of Bone Marrow Plasma Cells (BMPC) and Its Relationship with Interphase Cytogenetics and Prognosis in Multiple Myeloma (MM). (2009) (0)
PS1406 WEEKLY CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE UNTIL PROGRESSION IN RELAPSED REFRACTORY MULTIPLE MYELOMA (2019) (0)
MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma (2015) (0)
Faculty Opinions recommendation of Clinical course of patients with relapsed multiple myeloma. (2011) (0)
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma. (2023) (0)
P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY (2022) (0)
Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma (2012) (0)
MicroRNAs 15a and 16-1 regulates tumor proliferation in multiple myeloma. (2009) (0)
Global, Prospective, Non-interventional, Observational Study of Disease Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma (MM) Patients (pts): The INSIGHT MM Study (NCT02761187) (2017) (0)
The Effect of Insulin-Like Growth Factor 1 on Waldenstrom Macroglobulinemia (2008) (0)
MicroRNA Signature in Waldenstrom Macroglobulinemia (2008) (0)
Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study (2022) (0)
A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA). (2015) (0)
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail RRMM patients: A multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM). (2022) (0)
Faculty of 1000 evaluation for Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. (2011) (0)
P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 (2022) (0)
Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma (2015) (0)
B536 Gene Transcriptional Activity Analysis of the 6q Region in Waldenström Macroglobulinemia (2009) (0)
Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2022) (0)
Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM). (2009) (0)
Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study (2020) (0)
Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma (2022) (0)
Allogeneic Transplantation in Myeloma: Is It Worth a Price to Pay? (2011) (0)
A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy (2019) (0)
Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies. (2021) (0)
[Unusual evolution of autoimmune manifestations of a mantle zone lymphoma during a primary cytomegalovirus infection]. (1998) (0)
Hodgkin lymphoma and female fertility: a multicenter study in women treated with ABVD. (2022) (0)
Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia (2008) (0)
Chronic HCV Infection and Autologous Stem Cell Transplantation for Multiple Myeloma (2018) (0)
Melphalan flufenamide for relapsed/refractory multiple myeloma. (2022) (0)
Pomalidomide 3rd Line Versus 4th Line for RRMM (2018) (0)
1 Targeting NF-κ B in Waldenstrom Macroglobulinemia (2008) (0)
Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM). (2009) (0)
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study. (2023) (0)
Early Response Using Serum Immunoglobulin Free Light Chain (sFLC) Measurement Predicts Response to Therapy in Waldenstrom Macroglobulinemia (WM) (2008) (0)
Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma (2014) (0)
[New drug approval: Ciltacabtagene autoleucel - in patients with relapsed or refractory multiple myeloma who received 3 or more lines of therapy]. (2022) (0)
Don't Lose Your Cereblon (2012) (0)
Lenalidomide and Rituximab Combined with CEP Chemotherapy (R2CEP) for Patients with Relapsed or Refractory B-Cell Lymphoma (2018) (0)
B538 In Vivo Imaging Model of Multiple Myeloma and its Cellular Interaction with the Bone Marrow Milieu (2009) (0)
Weekly 20/56mg/m2 Carfilzomib, Lenalidomide and Dexamethasone until progression in Early Relapsed Refractory Multiple Myeloma (2019) (0)
Oral CHOP-like Chemotherapy in Elderly Patients with High-Grade Non Hodgkin B Cell Lymphoma (2018) (0)
S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04 (2022) (0)
The Crosstalk Between Leptin Receptor Activation and iNKT Mediated Anti-Tumor Immunity in Multiple Myeloma (2016) (0)
MM-133: HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) – Final Primary Analysis (2020) (0)
Cast nephropathy with light-chain disease in low grade lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (2012) (0)
B540 The Effect of Insulin-Like Growth Factor-1 in Waldenström Macroglobulinemia (2009) (0)
Multicenter ClinicalTrial of Bortezomib in Relapsed / Refractory Waldenstrom ’ s Macroglobulinemia : Results of WMCTGTrial 03-248 (2007) (0)
B526 PKC412, Small-Molecule Tyrosine Kinase Inhibitor, Regulates Survival in Waldenström Macroglobulinemia (2009) (0)
Peripheral Blood Stem Cell (PBSC) Harvest Is More Expensive Following Bortezomib-Based Therapy in Multiple Myeloma (MM), Related to Increase Number of Days of Collect. (2009) (0)
Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM). (2008) (0)
Pomalidomide 3rd line versus 4th line for in Early Relapsed Refractory Multiple Myeloma (2019) (0)
Bing Neel Syndrome: The French Experience (2014) (0)
ElotuzumabinCombinationWithLenalidomideandLow-Dose DexamethasoneinRelapsedorRefractoryMultipleMyeloma (2012) (0)
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study (2021) (0)
30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma (2023) (0)
Reply to Comment on low‐dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment‐free remission in chronic myeloid leukemia patients: Results of a retrospective study (2020) (0)
Risk and Response Adapted Conventional Treatment Strategy in 146 Patients with AL Amyloidosis (2014) (0)
P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (2022) (0)
Abnormal Expression of TRAF Adapter Proteins in Waldenstrom’s Macroglobulinemia. (2006) (0)
Recent advances in the treatment of multiple myeloma: a brief review (2022) (0)
Radioimmunotherapy of non Hodgkin’s lymphoma: the current state of art (2005) (0)
Impact Of Initial FGD-PET CT and Serum Free Light Chain On Transformation Of Solitary Plasmacytoma To MM (2013) (0)
Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status (2022) (0)
Longitudinal clonal architecture of acute myeloid leukemia with NPM1 driver insertion, early TET2 mutations and secondary e6a2 BCR-ABL1 rearrangement (2020) (0)
P-268: INSURE: a global pooled analysis of patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with ixazomib-lenalidomidedexamethasone (IRd) in routine clinical practice (2022) (0)
Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide (2014) (0)
The Tyrosine Kinase Src Regulates Adhesion and Survival in Waldenström Macroglobulinemia (2008) (0)
P-276: Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU cohort in France: IFM 2020-04 study (2022) (0)
Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma (2019) (0)
How I Treat Multiple myeloma in the geriatric patient. (2023) (0)
Faculty Opinions recommendation of Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. (2010) (0)
Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study (2019) (0)
Abstract #1393: MicroRNA in the biology, prognosis and therapy of Waldenstrom macroglobulinemia (2009) (0)
OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis (2022) (0)
[Circulating exosomal microRNA as biomarkers in mutiple myeloma]. (2017) (0)
The Unfolded Protein Response Is a Determinant of Disease Actvity in Waldenstrom’s Macroglobulinemia (WM). (2005) (0)
Plasma Cell Proliferation Using Ki67 Antigen Expression Defines Subgroups Related to Short Survival in Multiple Myeloma Especially with Low Beta-2 Microglobulin. (2006) (0)
Time to Improve Bortezomib and Lenalidomide Lines of Therapy (2017) (0)
Trial in Progress: Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing in Combination with Lenalidomide (R) and Dexamethasone (d) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) (2019) (0)
Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia (2010) (0)
Proteomic Analysis of Multiple Myeloma Identifies Upregulation of CRIK Protein, a Novel Protein Regulating Migration and Adhesion (2008) (0)
Prognostic Of IgD Myeloma In The Era Of Novel Agents (2013) (0)
Phase 1/2 Study of Orociep All Oral Regimen with Idarubicin, Cyclophosphamide, Etoposide, Prednisolone in Combination to Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma. Final Analysis (2017) (0)
Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia, (2011) (0)
SOCS1 and SOCS3 Genes Are Not Methylated In Waldenstrom Macroglobulinemia (2010) (0)
In Vivo Imaging Model of Multiple Myeloma and Its Cellular Interaction with the Bone Marrow Microenvironment (2008) (0)
Faculty Opinions recommendation of Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. (2010) (0)
Impfempfehlungen beim Multiplen Myelom: ein Konsensbericht des European Myeloma Network (2022) (0)
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial (2022) (0)
Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) (2021) (0)
Analysis of Familial Dysglobulinemia: a Multicenter IFM Study. (2009) (0)
Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM). (2012) (0)
Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (2022) (0)
A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3 (2022) (0)
B527 The Tyrosine Kinase Src Regulates Adhesion and Survival in Waldenström Macroglobulinemia (2009) (0)
University of Southern Denmark Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
The Interaction of CXCR4/SDF-1 and VLA-4 Regulates Adhesion and Transendothelial Migration in Waldenstrom Macroglobulinemia. (2007) (0)
receiving high-dose therapy 2-microglobulin produce a powerful myeloma staging system for patients β Chromosome 13 abnormalities identified by FISH analysis and serum (2013) (0)
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations (2020) (0)
A534 Perifosine: Final Results of a Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia (2009) (0)
Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia (2019) (0)
PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM). (2009) (0)
Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis, (2011) (0)
Le daratumumab, premier anticorps monoclonal anti-CD38 pour le traitement du myélome multiple (2017) (0)
Safety Profile Of Bortezomib Impacts Survival Of Cardiac AL Amyloidosis (2013) (0)
Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains (2017) (0)
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (2021) (0)
P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE (2022) (0)
MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma (2019) (0)
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM (2016) (0)
Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom’s Macroglobulinemia, the Role of the ERK and PKC Pathways. (2006) (0)
B539 Proteomic Analysis of Multiple Myeloma Identifies Upregulation of the Novel Protein CRIK (2009) (0)
MYC Overexpressing Multiple Myeloma Are Dependent on GLS1 (2019) (0)
Outcome at first relapse after frontline RVD regimen plus lenalidomide maintenance in transplant eligible MM patients. (2015) (0)
Memory loss during lenalidomide treatment: a report on two cases (2013) (0)
Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party (2016) (0)
Safety Profile of Bortezomib Impacts Survival in Light Chain Amyloidosis (2014) (0)
Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM) (2022) (0)
migration and homing in multiple myeloma dependent - Mechanisms of regulation of CXCR4/SDF-1 (CXCL12) (2013) (0)
Total Soluble HLAClass I and Soluble HLA-G inMultipleMyeloma andMonoclonal Gammopathy of Undetermined Significance (2005) (0)
B581 MicroRNA Regulate Growth and Angiogenesis in Multiple Myeloma (2009) (0)
Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis (2022) (0)
Abstract CT154: Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106) (2019) (0)
Proteasome inhibition regulates survival and homing in Waldenstrom Macroglobulinemia (WM) (2008) (0)
Efficacy and Safety Profile of Long Term Exposure to Lenalidomide in Relapsed Multiple Myeloma. (2012) (0)
P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma (2021) (0)
PF616 REAL-WORLD USE OF THE TRIPLET REGIMEN CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: A SUB-GROUP INTERIM ANALYSIS FROM A PROSPECTIVE OBSERVATIONAL STUDY (2019) (0)
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study (2022) (0)
Syddansk Universitet Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. (2022) (0)
B528 Dual PI3K and mTOR Inhibition in Waldenström Macroglobulinemia (2009) (0)
Weekly 20/56 mg/m² carfilzomib, lenalidomide, and dexamethasone until progression in early relapsed refractory multiple myeloma. (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Xavier Leleu?

Xavier Leleu is affiliated with the following schools:

University of Poitiers
University of Salamanca
Harvard University

Xavier Leleu's Academic­Influence.com Rankings

Why Is Xavier Leleu Influential?

Xavier Leleu's Published Works

Published Works

What Schools Are Affiliated With Xavier Leleu?

Xavier Leleu's AcademicInfluence.com Rankings